Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Unknown 1 Terminated 1 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Anemia 1

Interventions

Epoetin Alfa 9 Darbepoetin alfa 5 epoetin beta 3 telapristone acetate 2 fludarabine phosphate 2 fludarabine 2 Cyclophosphamide 2 Carboplatin 2 Busulfan 2 AP 1903 reagent 2 ACE-011 2 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2 venetoclax 1 vactosertib 1 trametinib 1 thymoglobulin 1 ruxolitinib 1 regorafenib 1 ponatinib 1 pertuzumab 1 pembrolizumab 1 peginesatide 1 palbociclib 1 olaparib 1 niraparib 1 neratinib 1 lorlatinib 1 lenvatinib 1 idelalisib 1 hematide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Anemia × Blood Transfusion × Clear all

NCT01116479 2014-11-05

HaemOPtimal

Rigshospitalet, Denmark

Phase 2 Terminated

Classical hematology

Anemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡